中药联合抗病毒药物治疗HBV所致肝纤维化的研究进展
|
摘要
就目前国内外中西医抗肝纤维化的治疗进行综述,探讨中西医治疗肝纤维化的基础理论及临床研究进展,为预防及治疗肝纤维化提供依据。
Therapies for hepatic fibrosis by integrative medicine at home and abroad were reviewed currently to discuss basic theory and clinical research progress of integrative medicine in the treatment for hepatic fibrosis,therefore to provide the reference for the prevention and treatment for hepatic fibrosis.
Therapies for hepatic fibrosis by integrative medicine at home and abroad were reviewed currently to discuss basic theory and clinical research progress of integrative medicine in the treatment for hepatic fibrosis,therefore to provide the reference for the prevention and treatment for hepatic fibrosis.
引文
[1]蔡庆春.鳖甲软肝丸联合替比夫定治疗慢性乙肝肝纤维化的临床观察[J].临床医药文献杂志,2015,2(26):5525-5526.
[2]张宁,黄坚.乙型肝炎病毒感染与肝星状细胞的活化增殖[J].实用肝脏病杂志,2013,16(4):366-368.
[3]Kobayashi M,Arase Y,Ikeda K,et al.Clinical characteristics of patients infected with bvirus genotypes AB and C[J].Hepatology,2002,37(1):35-39.
[4]王驭风,夏澍,钱卫.核苷类抗病毒药物治疗乙型肝炎肝硬化患者的疗效分析[J].实用临床医药杂志,2013,17(7):43-45.
[5]Liaw YF,Sung JJ,Chow WC,et al.Lamivudine for patients with chronic hepatitis B and advanced liver disease[J].N Engl J Med,2004,35(1):1521-1531.
[6]Lampertico P,Vigano M,Manenti E,et al.Low resistance to adefovir combined with lamivudine 3-year study of 145 lamivudine-resistant hepatitis B patients[J].Gastroenterology,2007,133(4):1445-1451.
[7]Hon J,Xu D,Shi G,et al.Five-year telbivudine treatment with effective viral suppression results in resolution of liver inflammation and fibrosis regression in patients with chronic hepatitis b[J].JHepatol,2011,54(6):S287.
[8]Chang TT,Liaw YF,Wu SS,et al.Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B[J].Hepatology,2010,52(6):886-893.
[9]Marcellin P,Heathcote EJ,Buti M,et al.Tenofovir disoproxil fumarateversus adefovir dipivoxil for chronic hepatitisB[J].N Engl J Med,2008,359(23):2442-2455.
[10]Maylin S,Martinot-Peignnoux M,Moucari R,et al.Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C[J].Gastroenterology,2008,135(6):821-829.
[11]Gish RG.Improving outcomes for patients with chronic hepatitis B[J].Curr Gastroenrol Rep,2007,23(9):14-22.
[12]杨伟峰,陈厚昌,夏笔军.丹参酮ⅡA对肝星状细胞增殖及分泌细胞外基质的影响[J].实用医学杂志,2003,19(11):191-192.
[13]张培林.PCⅢ检测丹参抗肝纤维化效力临床观察---附61例报告[J].中国中医急症,2012,11(2):103-105.
[14]李华伟.替比夫定联合扶正化瘀胶囊治疗慢性乙肝纤维化效果观察[J].吉林医药学院学报,2015,36(2):88-90.
[15]王英凯,王丹,彤宇.鳖甲为主的中药治疗肝纤维化的实验室和临床研究[J].临床肝胆病杂志,2002,18(4):253-254.
[16]王伟杰,席岳.尚立芝,等.柴胡疏肝散对肝纤维化患者肝功能、肝纤维化标志物及肝脾超声指标的影响[J].中药药理与临床,2017,33(5):166-168.
[17]王金周,程传浩.疏肝健脾汤对肝纤维化大鼠基质金属2、TIMP-2影响的研究[J].中医学报,2010,25(4):684-685.
[18]郜海生.乙肝清热解毒胶囊治疗慢性乙型肝炎疗效观察[J].中外医疗,2009,2(5):92-94.
[19]霍清萍,张延超.清热化淤方对慢性肝病肝纤维化及相关指标的影响[J].江苏中医,2000(11):9-11.
[20]施旭光,黄兆胜,吕健,等.虎金颗粒对免疫性肝纤维化大鼠肝功能和肝纤指标的影响[J].浙江中医药大学学报,2012,34(1):62-63.
[21]郭守强.苦参碱对肝纤维化大鼠转化生长因子β1表达的影响[J].西部中医药,2012,25(11):14-17.
[22]刘成.消黄方对大鼠胆汁淤积性肝纤维化的干预作用[J].西部中医药,2014,27(6):13-15.
[23]Lwaleed BA,Bass PS.Tissue factor pathway inhibitor:structure,biology and involvement in disease.The Journal of pathology,2006,20(8):327-339.
[24]袁恒杰.丹参素药理作用研究新进展[J].中国医院药学杂志,2006,26(5):644-646.
[25]缪卫华.活血化瘀在肝硬化腹水治疗中的地位和作用[J].现代中西医结合杂志,2007,16(31):460-462.
[26]吴樱樱,胡秀萍,朱虹,等.抗肝硬化复方的活血化瘀作用[J].安徽医科大学学报,2006,41(2):161-163.
[27]慕永平,刘平,刘莺,等.膈下逐瘀汤对进展期大鼠肝纤维化的抑制作用及其方证探讨[J].中医杂志,2006,47(3)):265-268.
[28]付丽,卢宁,周红.活血化痰法抗乙型肝炎肝纤维化的临床观察[J].中医药信息,2002,19(4):31-33.
[29]任小巧,卢跃卿,陈永旭,等.仲景三方对大鼠肝纤维化不同时期血清Ⅰ型前胶原、透明质酸及层粘蛋白作用的观察[J].北京中医药大学学报,2001,24(3):31-33.
[30]王亚玲.阿德福韦脂及联合复合丹参对慢性乙型肝炎肝纤维化指标的影响[J].临床和实验医学杂志,2007,6(6):88-89.
[31]刘志芬.肝脉柔合剂治疗慢性乙型肝炎肝纤维化105例[J].中西医结合肝病杂志,2007,17(2):114-115.
[32]杨惠敏,蒋春彦.软肝汤联合阿德福韦酯片治疗代偿期乙肝肝硬化42例[J].西部中医药,2017,30(12):82-84.
[33]王津生,王亚煌.安络化纤丸治疗慢性乙型肝炎早期肝硬化的疗效观察[J].中草药,2006,37(9):139-141.
[34]武向丽.水飞蓟宾对CCl4所致肝硬化门静脉高压大鼠的保护作用及其机制研究[J].西部中医药,2017,30(9):39-42.
[35]吴小洁.加味膈下逐瘀汤联合恩替卡韦片对治疗瘀血阻络型慢性乙肝临床研究[J].世界中西医结合杂志2017,12(11):1594-1596.
[36]陈秀清.丹参注射液联合恩替卡韦治疗慢性乙型肝炎肝纤维化的临床研究[J].现代药物与临床,2016,31(6):878-881.
[37]王亮亮.复方鳖甲软肝片联合阿德福韦酯治疗慢性乙肝肝纤维化临床研究[J].亚太传统医药,2017,13(9):136-137.
[38]张桂华,苏红宝,赵健.鳖甲软肝胶囊联合拉米夫定、阿德福韦酯片治疗失代偿期乙肝肝硬化临床观察[J].西部中医药,2013,26(2):1-4.
[39]闫雪华.恩替卡韦联合复方鳖甲软肝片治疗失代偿期乙肝肝硬化疗效观察[J].西部中医药,2014,27(7):84-86.
[2]张宁,黄坚.乙型肝炎病毒感染与肝星状细胞的活化增殖[J].实用肝脏病杂志,2013,16(4):366-368.
[3]Kobayashi M,Arase Y,Ikeda K,et al.Clinical characteristics of patients infected with bvirus genotypes AB and C[J].Hepatology,2002,37(1):35-39.
[4]王驭风,夏澍,钱卫.核苷类抗病毒药物治疗乙型肝炎肝硬化患者的疗效分析[J].实用临床医药杂志,2013,17(7):43-45.
[5]Liaw YF,Sung JJ,Chow WC,et al.Lamivudine for patients with chronic hepatitis B and advanced liver disease[J].N Engl J Med,2004,35(1):1521-1531.
[6]Lampertico P,Vigano M,Manenti E,et al.Low resistance to adefovir combined with lamivudine 3-year study of 145 lamivudine-resistant hepatitis B patients[J].Gastroenterology,2007,133(4):1445-1451.
[7]Hon J,Xu D,Shi G,et al.Five-year telbivudine treatment with effective viral suppression results in resolution of liver inflammation and fibrosis regression in patients with chronic hepatitis b[J].JHepatol,2011,54(6):S287.
[8]Chang TT,Liaw YF,Wu SS,et al.Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B[J].Hepatology,2010,52(6):886-893.
[9]Marcellin P,Heathcote EJ,Buti M,et al.Tenofovir disoproxil fumarateversus adefovir dipivoxil for chronic hepatitisB[J].N Engl J Med,2008,359(23):2442-2455.
[10]Maylin S,Martinot-Peignnoux M,Moucari R,et al.Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C[J].Gastroenterology,2008,135(6):821-829.
[11]Gish RG.Improving outcomes for patients with chronic hepatitis B[J].Curr Gastroenrol Rep,2007,23(9):14-22.
[12]杨伟峰,陈厚昌,夏笔军.丹参酮ⅡA对肝星状细胞增殖及分泌细胞外基质的影响[J].实用医学杂志,2003,19(11):191-192.
[13]张培林.PCⅢ检测丹参抗肝纤维化效力临床观察---附61例报告[J].中国中医急症,2012,11(2):103-105.
[14]李华伟.替比夫定联合扶正化瘀胶囊治疗慢性乙肝纤维化效果观察[J].吉林医药学院学报,2015,36(2):88-90.
[15]王英凯,王丹,彤宇.鳖甲为主的中药治疗肝纤维化的实验室和临床研究[J].临床肝胆病杂志,2002,18(4):253-254.
[16]王伟杰,席岳.尚立芝,等.柴胡疏肝散对肝纤维化患者肝功能、肝纤维化标志物及肝脾超声指标的影响[J].中药药理与临床,2017,33(5):166-168.
[17]王金周,程传浩.疏肝健脾汤对肝纤维化大鼠基质金属2、TIMP-2影响的研究[J].中医学报,2010,25(4):684-685.
[18]郜海生.乙肝清热解毒胶囊治疗慢性乙型肝炎疗效观察[J].中外医疗,2009,2(5):92-94.
[19]霍清萍,张延超.清热化淤方对慢性肝病肝纤维化及相关指标的影响[J].江苏中医,2000(11):9-11.
[20]施旭光,黄兆胜,吕健,等.虎金颗粒对免疫性肝纤维化大鼠肝功能和肝纤指标的影响[J].浙江中医药大学学报,2012,34(1):62-63.
[21]郭守强.苦参碱对肝纤维化大鼠转化生长因子β1表达的影响[J].西部中医药,2012,25(11):14-17.
[22]刘成.消黄方对大鼠胆汁淤积性肝纤维化的干预作用[J].西部中医药,2014,27(6):13-15.
[23]Lwaleed BA,Bass PS.Tissue factor pathway inhibitor:structure,biology and involvement in disease.The Journal of pathology,2006,20(8):327-339.
[24]袁恒杰.丹参素药理作用研究新进展[J].中国医院药学杂志,2006,26(5):644-646.
[25]缪卫华.活血化瘀在肝硬化腹水治疗中的地位和作用[J].现代中西医结合杂志,2007,16(31):460-462.
[26]吴樱樱,胡秀萍,朱虹,等.抗肝硬化复方的活血化瘀作用[J].安徽医科大学学报,2006,41(2):161-163.
[27]慕永平,刘平,刘莺,等.膈下逐瘀汤对进展期大鼠肝纤维化的抑制作用及其方证探讨[J].中医杂志,2006,47(3)):265-268.
[28]付丽,卢宁,周红.活血化痰法抗乙型肝炎肝纤维化的临床观察[J].中医药信息,2002,19(4):31-33.
[29]任小巧,卢跃卿,陈永旭,等.仲景三方对大鼠肝纤维化不同时期血清Ⅰ型前胶原、透明质酸及层粘蛋白作用的观察[J].北京中医药大学学报,2001,24(3):31-33.
[30]王亚玲.阿德福韦脂及联合复合丹参对慢性乙型肝炎肝纤维化指标的影响[J].临床和实验医学杂志,2007,6(6):88-89.
[31]刘志芬.肝脉柔合剂治疗慢性乙型肝炎肝纤维化105例[J].中西医结合肝病杂志,2007,17(2):114-115.
[32]杨惠敏,蒋春彦.软肝汤联合阿德福韦酯片治疗代偿期乙肝肝硬化42例[J].西部中医药,2017,30(12):82-84.
[33]王津生,王亚煌.安络化纤丸治疗慢性乙型肝炎早期肝硬化的疗效观察[J].中草药,2006,37(9):139-141.
[34]武向丽.水飞蓟宾对CCl4所致肝硬化门静脉高压大鼠的保护作用及其机制研究[J].西部中医药,2017,30(9):39-42.
[35]吴小洁.加味膈下逐瘀汤联合恩替卡韦片对治疗瘀血阻络型慢性乙肝临床研究[J].世界中西医结合杂志2017,12(11):1594-1596.
[36]陈秀清.丹参注射液联合恩替卡韦治疗慢性乙型肝炎肝纤维化的临床研究[J].现代药物与临床,2016,31(6):878-881.
[37]王亮亮.复方鳖甲软肝片联合阿德福韦酯治疗慢性乙肝肝纤维化临床研究[J].亚太传统医药,2017,13(9):136-137.
[38]张桂华,苏红宝,赵健.鳖甲软肝胶囊联合拉米夫定、阿德福韦酯片治疗失代偿期乙肝肝硬化临床观察[J].西部中医药,2013,26(2):1-4.
[39]闫雪华.恩替卡韦联合复方鳖甲软肝片治疗失代偿期乙肝肝硬化疗效观察[J].西部中医药,2014,27(7):84-86.